The collective data indicate that LAVA’s approach to recruit gamma delta T cells with its bispecific antibody platform results in potent anti-tumor activity while avoiding off-tumor toxicity and cytokine release syndrome (CRS), potentially translating in a superior therapeutic index compared to CD3-based T cell engagers
New non-human primate data support the safety and tolerability profile of LAVA’s lead solid tumor Gammabody™ programs
Recruitment is underway for the phase 1/2a clinical trial of LAVA-1207 for metastatic castration-resistant prostate cancer (mCRPC)
In preclinical experiments, LAVA-1207 has shown the ability to activate Vγ9Vδ2 (Vgamma9 Vdelta2) T cells to exert cytotoxicity toward PSMA (prostate specific membrane antigen)-expressing tumor cells at picomolar concentrations. Using prostate cancer patient samples, LAVA-1207 activated autologous Vγ9Vδ2 T cells and triggered lysis of tumor cells, while sparing normal prostate tissue. The mechanism of preferential tumor cell killing may be due to a demonstrated overexpression of a range of Vγ9Vδ2 T cell ligands on tumor cells. A first-in-human Phase 1/2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-1207 in patients with therapy refractory metastatic castration-resistant prostate cancer (mCRPC) is currently recruiting.
“We are grateful for the opportunity to discuss both our Gammabody™ technology and our first clinical-stage solid tumor program, LAVA-1207, at the
In addition, data from the non-human primate study showed an EGFR (epidermal growth factor receptor)-targeted surrogate Gammabody™ to be safe and well-tolerated in non-human primates. The EGFR Gammabody™ was administered at doses up to 23 mg/kg leading to high sustained plasma levels and dose-dependent accumulation in relevant tissues with no safety-related effects and no signs of cytokine release syndrome (CRS). LAVA’s clinical stage PSMA Gammabody™, LAVA-1207, is an Fc-containing Gammabody™ for which pre-clinical data from in vitro, ex vivo and in vivo models will also be presented.
“Solid tumors have proven an especially difficult challenge for CD3-based T cell engagers. First generation T cell engagers have shown a relatively high risk for CRS-related toxicities,” said
In the non-human primate study, animals were administered weekly intravenous doses of 1, 5 or 23 mg/kg of an EGFR gamma delta bsTCE that is fully cross-reactive with EGFR and Vγ9 T cells in non-human primates. At all doses, the EGFR gamma delta bsTCE only induced minimal levels of cytokines such as IL-2, IL-6 and IFN-gamma and there were no signs of CRS. No changes in general health parameters, clinical chemistry, hematology or histopathology were observed. The compound was pharmacologically active in the animals, with Vγ9-positive T cells expressing markers indicating activation (CD25 and CD69). Presence of the injected compound in EGFR-expressing tissues, such as skin, muscle and colon, was demonstrated using immune-histochemistry. The elimination half-life was similar to the half-life of regular human IgG and ranged between 84.7 and 127.4 hours.
About
LAVA’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including in respect of the company’s anticipated growth and clinical developments plans, including the timing of clinical trials. Words such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the preclinical data, clinical development and scope of clinical trials, and the potential use of our product candidates to treat various tumor targets. Many factors, risks and uncertainties may cause differences between current expectations and actual results including, among other things, the timing and results of our research and development programs and preclinical and clinical trials, our ability to obtain regulatory approval for and commercialize our product candidates, our ability to leverage our initial programs to develop additional product candidates using our Gammabody™ platform, and the failure of LAVA’s collaborators to support or advance collaborations or our product candidates. In addition, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
CONTACT
Chief Financial Officer
ir@lavatherapeutics.com
+1-917-763-2709
catherine@newdaybioconsulting.com
Source:
2022 GlobeNewswire, Inc., source